Plasma Sclerostin Level & Treatment of Osteomalacia (OMSOST)
The aim of this study is to determine plasma sclerostin levels and change in plasma sclerostin levels in patients with osteomalacia treated with calcium and vitamin D.
Patients with osteomalacia diagnosed and routinely treated with calcium and vitamin D will be included in the study. This is an observational study. The plasma sclerostin levels will be measured before and after osteomalacia treatment.
Endocrine System Diseases
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Plasma Sclerostin Level in Patients With Osteomalacia|
- Plasma sclerostin level [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Changes in plasma sclerostin level in patients with osteomalacia who are scheduled for routine treatment of osteomalacia
|Study Start Date:||March 2012|
|Study Completion Date:||May 2013|
|Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
This study is a prospective, observational, single-center study. Ethical approval was obtained from the Institutional Review Board.
This study will be completed with 40 patients with osteomalacia. An intravenous cannula will be inserted into the antecubital vein. Blood samples will be obtained before and after treatment.
Plasma will be collected and will be centrifuged for 15 minutes at 1000Xg within 30 minutes of collection. Aliquots of plasma will be added to eppendorf tubes and stored at -20°C.
Plasma sclerostin levels will be measured using a Human Sclerostin ELISA kit (Cusabio, Catalog No: CSB-E13146h, Newark, DE, USA). All assays will be performed according to the manufacturer's instructions. The minimum detectable concentration of human sclerostin is typically <0.012 ng/ml. Intra-assay precision is less than 8%.
|Bagcilar Training & Research Hospital|
|Principal Investigator:||MUHARREM CIDEM, MD||Bagcilar Training & Research Hospital Istanbul, Turkey|